STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News: At the Annual General Meeting on December 11, held in Stockholm, it was confirmed that Diamyd Medical (NASDAQ:DMYDY) (STO:DIAMB) is on track to file an IND application for a phase III study with the FDA in the US before year end.
